^
    Back
    Association details:
    Biomarker:LDH elevation
    Cancer:Melanoma
    Drug Class:PD-L1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    J Immunother
    Title:

    Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

    Published date:
    08/14/2020
    Excerpt:
    ...we analyzed real-world outcomes of first-line anti-PD-1 monotherapy in advanced melanoma patients...ECOG PS of ≥1, symptomatic brain metastases, and liver metastases were associated with inferior OS and, together with elevated LDH, with death before second-line treatment.
    DOI:
    10.1097/CJI.0000000000000334